Introduction

Challenges Faced by Emerging Markets and Developing Countries in Global Health Innovation Efforts
LMICs and LICs have been impacted by chronic disparities in the adoption and advancement of clinical trial and population health innovation efforts, due to conflicting regulatory requirements for Phase I to Phase IV clinical trial models primarily defined in the Western world [1, 2] . An excerpt from the WHO Public Health Innovation report [3] 
Examples of Impeded Progress in Emerging Markets: India
In the last two decades, India has become one of the most sought-after locations within the cluster of emerging markets for global clinical trials, due to its potential for fast recruitment of patients. However, India's ability to sustain its growth within the drug discovery domain continues to be significantly challenged by both regional and global regulatory changes [4] . According to Dr. Arun Bhatt, President of Clininvent Research Private Limited in Mumbai, India, the clinical trial protocols during this period of growth within India became more complex, demanding and inefficient for both the research teams and patients. Between 1999 and 2005 [4] , the average number of inclusion criteria increased threefold. The average number of procedures grew annually by 6.5%, reaching a median number of 35 procedures in 2005. In 2012, a typical phase III protocol included 50 eligibility criteria, 167 procedures and 13 endpoints [4] .
Gaps in Global Health Innovation
The root causes of these disparities are based on a lack of an agile technology infrastructure and robust ideation processes that can be adapted to their clinical research environments. Fragmented clinical trial processes and infrastructure deficiencies have left many promising research scientists with the inability to fully collaborate with their HIC peers. As a result, these researchers are unable to consistently partner on acute pandemic viral outbreaks, preventive medicine initiatives and new vaccine development that could save millions of lives. The International Council for Harmonisation (ICH) has identified the following unresolved areas of drug discovery innovation [5, 6] , shown below in Table 1: According to ICH, if these barriers are addressed, significant progress in the area of drug discovery and medical innovation can be achieved, resulting in [5, 6] a reduction in the costs of internal failures (rejects, reworks, reprocessing and investigations). This also includes optimized regulations to enable LMICs and LICs to meet drug discovery submission criteria and expedite the availability of medicines to patients. There are clear signs that the Healthcare and Life Science industries are ready to address these barriers, due to [7, 8] a growing demand for more focused research on infectious, rare, poverty-based and tropical diseases worldwide. In addition, there is a reinvigorated global movement towards clinical trial policy harmonization and acceptance of imported, de-identified clinical data sets for cross-trial analysis. Collectively, these changes in the Global Health Innovation community have resulted in the formation of new collaboration frameworks designed to bridge infrastructure and clinical intelligence disparities between HICs and LICs.
Pharmaceutical and Medical Innovation Model Approaches
In response to the change in the industry for expanded innovation worldwide, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has developed an innovation framework called the Pharmaceutical Innovation Platform (PIP). The focus of PIP is to provide a framework for a sustainable clinical innovation model, supported by collaborative partnerships, to achieve new heights in drug discoveries and healthcare solutions [9] . An excerpt from its PIP framework emphasizes this point [9] : 
Unresolved Areas of Drug Discovery within the Global Health
Innovation Community
Fragmented approaches to quality systems related to Good Clinical Practices (GCP) internationally Suboptimal deployment of limited resources to identify, enact or support effective elements of a quality system and continual improvement by both industry and regulatory agencies Delays may occur in the availability of medicines to patients round the world due to vast disparities in access to robust quality management systems and mature clinical trial practices Delays in the implementation of innovation and continual improvement of existing products may occur due to differences in expectation across differing regulatory bodies around the world Inability to implement consistently across stakeholder best practices related to Total Quality Management in other industries, which contributes to a lack of agility and repeatability in the quality of clinical trial practices The 3D Innovation Cycle is an iterative framework that consists of the following collaborative efforts for clinical innovation:
• Discovery:
• New/Improved Tools
• Preclinical and Clinical Development
• Market Approval and Manufacture
• Delivery The IFPMA's PIP model is composed of healthcare delivery characteristics that are necessary for an effective clinical innovation environment to grow locally, nationally and internationally [9] . Table 2 lists the attributes that the IFPMA outlines in its PIP model [9] .
• Getting Products to Patients
The model goes into greater detail regarding the tactical aspects of each of these areas. We saw in our research congruent themes between IFPMA, WHO and FDA in this regard, pertaining to scalable clinical innovation models for LMICs and LICs to use as their strategic compass in navigating towards locally sustainable research efforts. Table 3 is a summary of both the FDA's and WHO's adaptable innovation models.
The model ultimately enables LMIC and LIC innovators to transition from being the primary recipients of innovation, to originators of clinical innovation. It will also take bold and unconventional thinking in order to overcome the socioeconomic and infrastructure barriers that innovators face within these regions of the world. Both WHO and the FDA provided solid narrative guidance on implementation approaches to their models. However, there was limited evidence, beyond their illustrative examples, of the measurable outcomes of the use of these models by LMICs and LICs in our systematic review. This has inspired our thinking as healthcare innovators, to re-architect and integrate best practices from IFPMA, WHO, the FDA, and the new agile Open Source technology and Open Science frameworks, which are gaining greater acceptance as a platform of choice for clinical intelligence communities, as the next generation of collaborative research [10] .
Next Generation of LMIC and LIC Virtual Collaboration Models
The movement towards Open Source-Open Science collaboration is evident with the new e-health platforms that are taking shape to address these challenges. As the Global Health community enters into a broader range of eHealth adoption efforts, we see pioneering growth and expansion of mHealth (mobile phone technology used for healthcare data exchange and patient engagement) solutions that are taking a progressive approach to enabling more effective patient engagement and peer-to-peer clinical decision support at the point of care. This has also led to supporting new patient engagement research models for public health bio-surveillance and education efforts related to infectious disease prevention and control and medication adherence in LIC and LMIC regions of the world. As a result, some mHealth initiatives have moved the needle with the adoption of new patient engagement efforts, simply due to leveraging this new technology. Yet it is still in its infancy as a stand-alone solution that ignites locally based clinical innovation. The impact and sustainability of clinical innovation powered by mHealth solutions are still uncertain, due to the following factors outlined by WHO in its 2015 guide for mHealth solutions [11] , shown in Table 4 below:
The goal of an integrated Open Source-Open Science platform is to take mHealth one step further, by enabling re-usable clinical intelligence that can be shared and redistributed in the context of clinical innovation before, during and after care is delivered. As a result, mHealth thus becomes an essential building block to this framework by providing a timely data feed for the innovation process. When mHealth is coupled with an Open Source-Open Science virtual collaboration environment, it will enable LMIC and LIC research scientists to engage in interactive drug discovery and global knowledge sharing for clinical innovation. As a result, it may reduce drug discovery lag time, by enabling timely collaborative clinical trial data sharing and bio-surveillance intelligence across all phases of drug discovery.
Conceptual Open Source-Open Science System Design Approach
Our conceptual Open Source-Open Science model, Project Orchid, incorporates the above requirements, in order to strengthen existing clinical trial partnerships and support new collaborative efforts that have disparate geographic, cultural and regulatory drivers. We have designed an integrated operational governance and clinical innovation engagement platform that can be adapted to the needs of each stakeholder organization. The intent of our model is to illustrate, through a multi-national TB clinical trial cohort, the potential outcomes of using the Open SourceOpen Science framework (Table 5 ).
Open Source-Open Science Innovation Framework
Project Orchid consists of two integrated offerings: An Innovation Engagement Framework and a technologyenabled Collaboration Platform (Figures 1 and 2 discovery environment and best practices framework, to harmonize their clinical trial and public health programme governance approaches to produce improved research and care delivery outcomes.
Open Science Collaboration Maturity Model
Our proposed Open Science Collaboration Maturity Model is used to identify and address current process, resource and competency gaps and disparities in key areas that impede medical innovation across the group of stakeholder organizations. This exercise will enable innovation teams to apply knowledge management, process harmonization and re-engineering techniques and risk mitigation strategies to bridge potential points of failure within the collaboration effort. The model is a process performance hierarchy, designed to address peerto-peer organizational disruption, due to change manage- • Programme and Policy Harmonization: This consists of addressing regulatory and cross-cultural organizational dynamics, process adoption and motivation models.
• Ideation and Strategy: This consists of addressing medical innovation modelling and clinical trial bridging strategies.
• Operational Engagement: This consists of facilitating, across the cohorts, the identification of service-level key performance indicators, knowledge management and delivery system optimization efforts after the launch of their medical innovation.
The structure of the model is to encourage transparency and process agility, while leveraging the collective strengths of all stakeholder organizations in order to accelerate opportunities for business development, product innovation and service management in a more fluid manner. This framework aligns to the ICH Quality System concept tenets: Process Performance and Product Quality Monitoring System Corrective Action/Preventive Action (CA/PA); System Change Management; System Management Review; Knowledge Management and Quality Risk Management [5, 6] . Each level of the maturity model corresponds to a key set of measures and methods that a collaborative partnership focuses on in its efforts to enable sustainable innovation. A facilitated Strengths, Weaknesses, Opportunities and Threats (SWOT) analysis is done across all core stakeholders of the partnership to determine how to address disparities in the "as-is" and "to-be" model for collaboration, followed by a risk mitigation and change management governance model adopted at all levels of the joint venture. The structure of the model is to encourage transparency and process agility, while leveraging the collective strengths of all stakeholder organizations in order to accelerate opportunities for business development, product innovation and service management in a more fluid manner [10] [11] [12] [13] .
It is recommended that, prior to initiating a formal collaborative partnership, an organization should perform a selfassessment to be fully aware of its SWOT findings and perform an internal cognitive walkthrough, or "what if" scenario with potential partnerships, in preparation for change management stressors or business drivers that may be encountered as part of the harmonization effort for joint ventures [12, 13] . The table below (Table 6 ) itemizes each level of the maturity model and how it is applied across all three domains of the collaboration framework.
Clinical Trial Data Quality and Regulatory Policy Harmonization
The incremental nature of the Collaboration Maturity Model can be applied when multi-national research teams with LIC and LMIC partners attempt to harmonize the following GCP frameworks and regulatory standards that align to key bioethics and privacy guidelines related to the Clinical Trial Data Management system used in the Life Science industry. They include, at a minimum, the standards listed in Table 7 :
Open Source-Open Science Solution Architecture and System Design
A proposed Open Source-Open Science Collaboration solution architecture should leverage Open Source technology frameworks for 2D and 3D data visualization and healthcare interoperability standards, such as HL7 Fast Healthcare Interoperability Resource (FHIR), Clinical Data Architecture (CDA) and Digital Imaging and Communication in Medicine (DICOM) standards, which are widely used in electronic medical records, medical devices, picture archiving systems and registries worldwide, to enable system-to-system integration and data exchange across the clinical research and care management continuum [13] [14] [15] [16] [17] [18] [19] [20] .
Open Source-Open Science platforms, like Project Orchid, will also leverage technology components, such as Linux and Drupal, and long-term scalable telecommunication frameworks, such as Internet2 and Unified Communication protocols, which optimize secured clinical data exchange in low bandwidth regions of the world. The proposed implementation model for Project Orchid is to incorporate these standards (Table 8) within Project Orchid's capabilities as a shared Platform-as-a-Service offering, to enable global pharmaceutical and biotechnology firms and government-based Life Science agencies to bridge the clinical data exchange connectivity divide with their LIC and LMIC pilot sites, which have very limited IT and mHealth infrastructure resources.
Unified Communication and Usability Standards
The following table (Table 9 ) is a partial list of the protocols and standards that will be used in the development of the Unified Communications recommended by Texas A&M Internet2 Technology and Evaluation Center (ITEC).
We will also use the ISO 9241-11 standard to verify the following criteria for user interface design, recommended by Virginia Tech's Advanced Research and Computing, Visionarium Lab: effectiveness, efficiency and satisfaction (ISO 1998 ). This will take into account both the visually and hearing impaired as well. The use of these standards will ensure effective adoption across diverse organizational, language and cultural attributes for our proposed multinational pilot programme.
Open Science User Profiles
In order to ensure that each member of the initiative has the appropriate access rights to the Open Source-Open Science Platform, the system will provide role-based capabilities to maintain the data integrity of the system and ensure alignment to Good Clinical Practices (GCP). Table 10 is a limited representation of a typical user profile configuration that a Clinical Research Organization (CRO) may collaborate with.
Implementation Model for an Open Source-Open Science Initiative
In order to illustrate how an Open Source-Open Science platform can be implemented for a viable clinical innovation effort across multi-national stakeholders, Project Orchid has targeted two scenarios: a multi-national Phase 
Multi-National TB Phase II/III Clinical Trial Toxicity and Efficacy 3D Bio-surveillance
The scope of the proof of concept and pilot is to build, test and deploy, in the field, an Open World Clinical Trial Collaboration Metaverse ecosystem between several central and sub-Saharan African countries, India, and the US, to facilitate a TB Vaccine Toxicity and Efficacy crosstrial data sharing initiative. The technology platform will simulate a vaccine development initiative across these locations with a shared virtual collaboration network that has a 2D/3D Genomic Toxicity and Efficacy Avatar environment, to detect and monitor toxicity and efficacy outcomes of specific formularies in Phase II/III TB clinical trials. The Human Avatar will display growing or diminishing contraindications that are reported via Case Report Forms from the participating researchers, as well as other relevant data feeds, such as laboratory information sys- • This is the standard that allows the transmission of emergency alert mass notifications Below are diagrams ( Figures 3 and 4 ) that illustrate the Project Orchid conceptual collaboration platform.
Conclusion
The current solutions in the LIC and LMIC clinical innovation domain are primarily third party vendor systems, which require unsustainable IT infrastructure and software management support, or heavily paper-based processes supplemented with standard IT desktop applications and databases. There are also very limited Open Source-Open Science, health information exchange and mHealth networks that are integrated into multi-national cohorts and these do not address the dynamic clinical trial frameworks used in drug discovery. Collectively, these systems do not enable the robust capabilities needed to sustain near-real time clinical innovation or meet the regulatory standards for compliance to GCP systems for clinical trial data management. As a result, LICs and LMICs cannot transition effectively from manual administrative efforts in order to participate in multi-national clinical trials and public health innovation, which directly impedes their ability to mature as an organization. The opportunity for innovation empowerment is within reach for emerging markets and LMICs, when global ingenuity meets Open Source-Open Science technology.
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